Startup investors may not be hitting the pause button entirely on venture capital deployment, but they certainly scaled back on mega-rounds over the past week. While the market continues to see robust interest in transformative technologies, only two startup financings crossed the multiple-hundred-million-dollar threshold during the tracking period.
The largest transaction of the week went to AI infrastructure provider Modal Labs, which pulled in a staggering $750 million. Trailing at a distance was construction automation unicorn Icon, which secured $200 million. Beyond these two giants, capital flowed heavily into specialized sectors including biotech, advanced insurance, health tech, and artificial intelligence infrastructure, showcasing a market that remains active even if top-line financing sizes experienced a modest contraction compared to previous weeks.
Topping the charts, New York-headquartered Modal Labs secured $750 million in a Series D funding round led by Accel. The massive infusion values the cloud infrastructure provider for AI inference and related applications at an impressive $15.75 billion. Modal Labs has captured widespread attention in the tech ecosystem due to its rapid commercial expansion, recently announcing that it has exceeded an annual revenue run rate of $1 billion. As companies across all industries race to build and deploy complex AI systems, demand for high-performance inference infrastructure has skyrocketed, positioning Modal Labs as one of the standout beneficiaries of the generative AI boom.
Securing the second-largest spot on the weekly tally was Austin-based Icon. The robotic construction systems developer, widely recognized for its pioneering work in 3D-printed homes, closed a $200 million Series D funding round co-led by institutional heavyweights Baillie Gifford and BlackRock. Icon’s technology addresses some of the most persistent labor and supply chain bottlenecks in the residential and commercial real estate sectors. According to the company, the fresh capital will help fuel its continued expansion as it targets a fourfold increase in revenue growth throughout 2026.
Biotechnology and genetic medicine also attracted substantial venture backing, dominating the middle tier of the week’s largest transactions. In Boston, Soufflé Therapeutics—a developer focused on innovative RNA therapies—raised $135 million in a Series B funding round. The financing was led by Juvia Group as part of a large and diverse syndicate of institutional and strategic investors, highlighting sustained confidence in RNA-based modalities following years of clinical and commercial validation across the broader life sciences industry.
Meanwhile, across the country in Menlo Park, California, Estuary Biotherapeutics officially launched with an impressive $103 million in total financing. The company is dedicated to developing advanced genetic medicines designed specifically for patients suffering from serious kidney diseases. The launch package comprises $93 million in a Series A round led by RA Capital Management, alongside $10 million in previously undisclosed seed capital, giving the young biotech firm a robust financial runway to advance its preclinical pipeline toward clinical trials.
Artificial intelligence applications and developer tooling continued to command significant venture dollars as well. San Francisco-based Labelbox, which builds specialized technology to train and evaluate AI models while helping organizations deploy intelligent agents that improve over time through experience, picked up $100 million in Series E funding. Infinitum Partners led the financing for the eight-year-old enterprise software provider, which continues to capitalize on the corporate imperative for high-quality data labeling and model refinement.
Healthcare technology also saw significant investment activity. Redwood City, California-based Suki announced a $90 million Series E financing round backed by firms including Healthier Capital and Crosslink Capital. Suki provides advanced artificial intelligence tools designed to alleviate administrative burnout among medical professionals by seamlessly converting natural clinical conversations into structured intelligence for medical documentation, coding, and other complex healthcare workflows.
In the specialized consumer and caregiving space, San Francisco-based Abby Care closed on $82 million in Series C funding. Backed primarily by Transformation Capital, the five-year-old startup operates a platform that empowers family members to become certified, paid caregivers capable of delivering professional-grade care directly in the home. The funding reflects a growing investor appetite for technology-enabled care solutions that address critical labor shortages in eldercare and specialized family support.
Climate and environmental risks also drove major venture investments this past week. Stand, a San Francisco-based insurance provider specializing in coverage for residential properties located in regions facing higher risks of natural disasters, secured $70 million in a Series C funding round. The financing values the three-year-old insurtech company at $1 billion, pushing it into unicorn status as insurers grapple with the growing frequency and severity of climate-related property losses. Saga Ventures Management led the financing round.
Hardware and semiconductor innovation rounded out the prominent rounds of the week. Portland, Oregon-based Mueon Corp., a semiconductor systems company constructing a modular platform specifically designed for AI and hyperscale computing workloads, completed a $65 million Series A funding round led by Maverick Silicon. Additionally, New York-based North.cloud raised $60 million in a Series B round led by PeakSpan Capital. North.cloud operates an infrastructure spend intelligence and automation platform that helps organizations monitor and optimize their mounting cloud and artificial intelligence expenditures.
These transactions form part of the broader macroeconomic and venture landscape tracked continuously through the Crunchbase dataset. Market analysts note that while the sheer volume of nine-figure rounds fluctuates week by week, investors remain highly selective, concentrating capital heavily on companies demonstrating clear enterprise traction, massive market demand, or breakthrough technological advantages in sectors like artificial intelligence, healthcare, and infrastructure.
